CoChat
Sign Up
Cited by 78

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Statins use and risk of dementia: A dose–response meta analysis

Zhang, Xiaoyu, Wen, Jianzhong, Zhang, Zhiqiang·2018·Medicine
DOI 10.1097/md.0000000000011304PMC PMC6078755
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000011304

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Statins are associated with decreased Aβ formation, attributed to the reduction in cholesterol which in turn regulates BACE1.

    “Statins are associated with decreased Aβ formation, attributed to the reduction in cholesterol which in turn regulates BACE1.”

    From BACE1: More than just a β‐secretase (2022) · cites this paper as [180]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. Newman, 1996, Carcinogenicity of lipid-lowering drugs, JAMA, 275, 55, 10.1001/jama.1996.03530250059028 · DOI
  2. Cucchiara, 2001, Use of statins in CNS disorders, J Neurol Sci, 187, 81, 10.1016/S0022-510X(01)00529-9 · DOI
  3. Vaughan, 2003, Prevention of stroke and dementia with statins: effects beyond lipid lowering, Am J Cardiol, 91, 23B, 10.1016/S0002-9149(02)03270-8 · DOI
  4. Gu, 2014, Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012, NCHS Data Brief, 177, 1
  5. Chong, 2001, Clinically relevant differences between the statins: implications for therapeutic selection, Am J Med, 111, 390, 10.1016/S0002-9343(01)00870-1 · DOI
  6. Stroup, 2000, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group, JAMA, 283, 2008, 10.1001/jama.283.15.2008 · DOI · Paper page
  7. Stang, 2010, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur J Epidemiol, 25, 603, 10.1007/s10654-010-9491-z · DOI · Paper page
  8. Orsini, 2012, Meta-analysis for linear and nonlinear dose–response relations: examples, an evaluation of approximations, and software, Am J Epidemiol, 175, 66, 10.1093/aje/kwr265 · DOI
  9. Zissimopoulos, 2017, Sex and race differences in the association between statin use and the incidence of Alzheimer disease, JAMA Neurol, 74, 225, 10.1001/jamaneurol.2016.3783 · DOI · Paper page
  10. Zamrini, 2004, Association between statin use and Alzheimer's disease, Neuroepidemiology, 23, 94, 10.1159/000073981 · DOI
  11. Sparks, 2008, Reduced risk of incident AD with elective statin use in a clinical trial cohort, Curr Alzheimer Res, 5, 416, 10.2174/156720508785132316 · DOI · Paper page
  12. Smeeth, 2009, Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials, Br J Clin Pharmacol, 67, 99, 10.1111/j.1365-2125.2008.03308.x · DOI
  13. Hippisley-Cox, 2010, Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database, BMJ, 340, c2197, 10.1136/bmj.c2197 · DOI
  14. Green, 2006, Statin use and the risk of Alzheimer's disease: the MIRAGE study, Alzheimers Dement, 2, 96, 10.1016/j.jalz.2006.02.003 · DOI
  15. Glasser, 2010, The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study, Clin Cardiol, 33, 280, 10.1002/clc.20758 · DOI
  16. Beydoun, 2011, Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment, J Epidemiol Community Health, 65, 949, 10.1136/jech.2009.100826 · DOI
  17. Benito-León, 2010, Statins and cognitive functioning in the elderly: a population-based study, J Alzheimers Dis, 21, 95, 10.3233/JAD-2010-100180 · DOI
  18. Zandi, 2005, Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study, Arch Gen Psychiatry, 62, 217, 10.1001/archpsyc.62.2.217 · DOI
  19. Wolozin, 2007, Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease, BMC Med, 5, 20, 10.1186/1741-7015-5-20 · DOI
  20. Williams, 2015, Lower risk of Alzheimer's disease mortality with exercise, statin, and fruit intake, J Alzheimers Dis, 44, 1121, 10.3233/JAD-141929 · DOI
  21. Szwast, 2007, Association of statin use with cognitive decline in elderly African Americans, Neurology, 69, 1873, 10.1212/01.wnl.0000279333.77404.d7 · DOI
  22. Rea, 2005, Statin use and the risk of incident dementia: the Cardiovascular Health Study, Arch Neurol, 62, 1047, 10.1001/archneur.62.7.1047 · DOI
  23. Parikh, 2011, Risk factors for dementia in patients over 65 with diabetes, Int J Geriatr Psychiatry, 26, 749, 10.1002/gps.2604 · DOI
  24. Masse, 2005, Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease, J Neurol Neurosurg Psychiatry, 76, 1624, 10.1136/jnnp.2005.063388 · DOI
  25. Mandas, 2014, Cognitive impairment and age-related vision disorders: their possible relationship and the evaluation of the use of aspirin and statins in a 65 years-and-over Sardinian population, Front Aging Neurosci, 6, 309, 10.3389/fnagi.2014.00309 · DOI
  26. Lin, 2015, Early statin use and the progression of Alzheimer disease: a total population-based case–control study, Medicine (Baltimore, 94, e2143, 10.1097/MD.0000000000002143 · DOI
  27. Li, 2010, Age-varying association between statin use and incident Alzheimer's disease, J Am Geriatr Soc, 58, 1311, 10.1111/j.1532-5415.2010.02906.x · DOI
  28. Li, 2004, Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study, Neurology, 63, 1624, 10.1212/01.WNL.0000142963.90204.58 · DOI
  29. Ancelin, 2012, Lipid lowering agents, cognitive decline, and dementia: the three-city study, J Alzheimers Dis, 30, 629, 10.3233/JAD-2012-120064 · DOI
  30. Jick, 2000, Statins and the risk of dementia, Lancet, 356, 1627, 10.1016/S0140-6736(00)03155-X · DOI
  31. Hendrie, 2015, Statin use, incident dementia and Alzheimer disease in elderly African Americans, Ethn Dis, 25, 345, 10.18865/ed.25.3.345 · DOI
  32. Hajjar, 2002, The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment, J Gerontol A Biol Sci Med Sci, 57, M414, 10.1093/gerona/57.7.M414 · DOI
  33. Haag, 2009, Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study, J Neurol Neurosurg Psychiatry, 80, 13, 10.1136/jnnp.2008.150433 · DOI · Paper page
  34. Cramer, 2008, Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study, Neurology, 71, 344, 10.1212/01.wnl.0000319647.15752.7b · DOI
  35. Corrao, 2013, Long-term use of statins reduces the risk of hospitalization for dementia, Atherosclerosis, 230, 171, 10.1016/j.atherosclerosis.2013.07.009 · DOI
  36. Chou, 2014, Statin use and incident dementia: a nationwide cohort study of Taiwan, Int J Cardiol, 173, 305, 10.1016/j.ijcard.2014.03.018 · DOI
  37. Bettermann, 2012, Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study, J Stroke Cerebrovasc Dis, 21, 436, 10.1016/j.jstrokecerebrovasdis.2010.11.002 · DOI
  38. Arvanitakis, 2008, Statins, incident Alzheimer disease, change in cognitive function, and neuropathology, Neurology, 70, 1795, 10.1212/01.wnl.0000288181.00826.63 · DOI
  39. Chen, 2014, Effects of statins on incident dementia in patients with type 2 DM: a population-based retrospective cohort study in Taiwan, PLoS One, 9, e88434, 10.1371/journal.pone.0088434 · DOI
  40. Ritchie, 2002, The dementias, Lancet, 360, 1759, 10.1016/S0140-6736(02)11667-9 · DOI
  41. Scarpini, 2003, Treatment of Alzheimer's disease: current status and new perspectives, Lancet Neurol, 2, 539, 10.1016/S1474-4422(03)00502-7 · DOI
  42. Mathis, 2017, The US Food and Drug Administration's perspective on the new antipsychotic pimavanserin, J Clin Psychiatry, 78, e668, 10.4088/JCP.16r11119 · DOI
  43. Wong, 2013, Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding, Pharmacoepidemiol Drug Saf, 22, 345, 10.1002/pds.3381 · DOI
  44. Rojas-Fernandez, 2015, Statins and cognitive side effects: what cardiologists need to know, Cardiol Clin, 33, 245, 10.1016/j.ccl.2015.02.008 · DOI
  45. Petanceska, 2003, Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol, J Mol Neurosci, 20, 395, 10.1385/JMN:20:3:395 · DOI
  46. Kandiah, 2009, Therapeutic potential of statins in Alzheimer's disease, J Neurol Sci, 283, 230, 10.1016/j.jns.2009.02.352 · DOI
  47. Refolo, 2001, A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease, Neurobiol Dis, 8, 890, 10.1006/nbdi.2001.0422 · DOI
  48. Gibson Wood, 2003, Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease, Biochim Biophys Acta, 1610, 281, 10.1016/S0005-2736(03)00025-7 · DOI
  49. Sun, 2003, Pravastatin inhibits pro-inflammatory effects of Alzheimer's peptide Abeta (1–42) in glioma cell culture in vitro, Pharmacol Res, 47, 119, 10.1016/S1043-6618(02)00288-8 · DOI

Cited by

Sorted by citations

Metadata

Authors
Zhang, X., Wen, J., & Zhang, Z.
Venue
Medicine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2018-07
Volume
97
Issue
30
Pages
e11304
ISSN
0025-7974
DOI
10.1097/md.0000000000011304
PMC
PMC6078755
Cited by
78
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review